Galera Therapeutics, Inc. entered into an agreement on October 15, 2025, to sell its dismutase mimetic assets (including avasopasem and rucosopasem) to Biossil Inc., with the transaction's liabilities assumed by Biossil. The assignment was formally communicated on October 21, 2025, to Blackstone, which agrees to direct any obligations to Biossil.